TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study in Nature Aging identified SRSF1, a gene encoding an RNA-processing factor, as a candidate for cell rejuvenation. It reduced several aging-related features in human skin fibroblasts and was associated with a 14% longer lifespan in treated mice; the results do not establish safety or benefit in people.
Researchers have identified SRSF1 as a candidate gene for countering some features of aging, reporting that it shifted gene-expression age measures in aged human skin cells and was linked to a 14% lifespan extension in mice. The study, published in Nature Aging, points to a possible alternative to Yamanaka-factor reprogramming, but it does not show that the approach is safe or effective in people.
The team first developed a machine-learning age predictor based on gene-expression profiles from human skin fibroblasts. The algorithm was trained on data spanning multiple aging processes and was used to estimate the cells’ “transcriptomic age.” Researchers tested it in fibroblast cell lines from donors aged 55, 65 and 79, including after interventions intended to change cell aging.
Using that predictor as a readout, the researchers screened a focused set of genes for candidates that could make aged cells register as more youthful. SRSF1, which encodes an RNA-processing factor, ranked highest. In the cell experiments, its over-expression reduced features associated with cellular senescence, proteostatic stress and inflammaging, the report said. These are laboratory measures; they do not by themselves establish that cells or tissues functioned better over the long term.
The team also delivered SRSF1 to aged mice. The gene primarily accumulated in the liver, and the treated animals showed a reduced rate of aging and lived 14% longer, according to the report. The source material does not provide the number of animals, the study’s full treatment details, or the statistical analysis behind the lifespan result. The findings therefore remain preclinical and need to be assessed in the context of the complete study.
A Candidate Beyond Yamanaka Factors
The study addresses a central challenge in cell rejuvenation: researchers want to reduce age-related changes without erasing the identity of specialized cells. Yamanaka factors can reprogram mature cells toward a pluripotent state, but that loss of specialization and concerns about cancer risk have made controlled therapeutic use difficult. The new work proposes SRSF1 as a different candidate, rather than showing that those risks have been resolved.
The approach also offers a screening tool. A gene-expression age score could help researchers compare interventions and identify candidates without relying solely on epigenetic clocks, which study co-author Alex Plesa said can be costly and difficult to interpret at scale. If validated, such a measure may help prioritize experiments. It is not yet a clinical test, and a younger transcriptomic score should not be treated as proof of improved health or longer life.
For readers, the key distinction is between a laboratory result and a therapy. The reported mouse lifespan finding makes SRSF1 a target for further research, but it does not establish a way to slow human aging. Questions about delivery, dosage, effects in different organs, long-term safety and potential cancer risk remain open.
red light therapy panels for skin rejuvenation
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Team Measured Cell Age
Partial reprogramming research grew from the discovery that expressing four Yamanaka factors can reset mature cells toward an undifferentiated state. Shorter exposure has been studied as a way to restore some youthful characteristics while retaining cell specialization. However, the source report notes concerns that excessive expression can increase cancer risk, prompting researchers to look for other molecular targets.
For this study, the researchers built an age predictor from transcriptomic profiles—measurements of gene activity—across several aging processes in skin fibroblasts. Plesa described the method as combining signals from different processes, analogous to odometers that track separate parts of a car. The model was tested against experimental interventions, including Yamanaka factors, before being used to screen genes for effects on aged cells.
The research was led by George Church of Harvard University’s Wyss Institute, with Plesa and collaborators from CIC bioGUNE-BRTA in Spain. The report says the work was published in Nature Aging. Church described the project as part of a longer effort to find genetic strategies that could extend healthspan, but that goal remains distinct from the results demonstrated in this study.
“In reprogramming, there is a fundamental tradeoff between rejuvenation and cell identity; achieving one without losing the other requires walking a fine line.”
— Alex Plesa, Ph.D., study co-first author
Human Safety and Benefit Unproven
The reported evidence comes from cell experiments and aged mice; the source material describes no human trial. It is not yet clear whether SRSF1 can be delivered safely and effectively to relevant tissues in people, whether its effects persist, or what dose and duration would be appropriate. The report also does not specify the full animal-study design or provide enough detail to evaluate the 14% lifespan result independently.
Preserving cell identity is an important research aim, but the material provided does not establish how completely the treated cells retained their specialized functions or whether SRSF1 has unwanted effects in other cell types. The cancer risks associated with Yamanaka factors are part of the motivation for finding other targets; the report does not establish that SRSF1 is free of comparable or different safety concerns.
Validation Before Clinical Testing
The immediate next step is independent and follow-up research to reproduce the cell and mouse findings, clarify how SRSF1 produces its effects, and assess long-term safety. Researchers would also need to determine whether the gene’s effects extend beyond the liver, where it primarily accumulated in the reported mouse work, and whether the result holds across different ages, tissues and disease conditions.
Any move toward human use would require a suitable delivery method, careful dose testing and evidence that the intervention improves meaningful health outcomes rather than only changing an age-related molecular score. The source material does not announce a clinical trial or provide a timeline for one. For now, SRSF1 is a preclinical research target, not an established rejuvenation treatment.
Key Questions
What did the researchers find?
They reported that over-expressing SRSF1 reduced several aging-associated features in human skin fibroblasts. In aged mice, treatment was associated with a reported 14% increase in lifespan.
Was the therapy tested in people?
No human trial is described in the source material. The findings are from cell experiments and mouse research, so human safety and benefit have not been established.
How is SRSF1 different from Yamanaka factors?
Yamanaka factors can reprogram mature cells toward a pluripotent state. The study investigated SRSF1, an RNA-processing factor, as a possible way to affect aging-related features without relying on that broad reprogramming approach. The report does not prove that SRSF1 preserves cell identity in every setting or is safer.
What does a 14% lifespan extension mean?
The report says aged mice treated with SRSF1 lived 14% longer. It is an animal-study result, not evidence of a similar effect in humans; the source material does not provide the full study details needed to assess the comparison.
When could this become a treatment?
No human-trial timeline is provided. Researchers would need to validate the results and establish delivery, dosage and long-term safety before clinical use could be considered.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
